| The University of Rochester Patent applications |
| Patent application number | Title | Published |
| 20110289605 | Animal Model for Osteoarthritis and Intervertebral Disc Disease - Provided herein is a transgenic animal whose genome comprises a first nucleic acid sequence encoding a fusion polypeptide, wherein the fusion polypeptide comprises a Cre recombinase and a mutated ligand binding domain of human estrogen receptor (CreER), wherein the first nucleic acid is operably linked to a chondrocyte-specific promoter and a second nucleic acid sequence encoding a β-catenin polypeptide, wherein the second nucleic acid sequence comprises one or more loxP sequences. Also provided is a method of modifying a transgenic animal comprising administering tamoxifen to the transgenic animal. Also provided are methods of screening for an agent that reduces or prevents Cre-Negative Control one or more symptoms of osteoarthritis or intervertebral disc disease in a subject. Methods for identifying a subject with or at risk of developing osteoarthritis or intervertebral disc disease are also provided, as well as methods of treating or preventing osteoarthritis or intervertebral disc disease in a subject. | 11-24-2011 |
| 20110268748 | NURR-1 Interacting Protein (NuIP) - Provided herein are methods of promoting the activity of Nurr1 in a cell comprising contacting the cell with NuIP or an analog or fragment thereof. Also provided are methods of treating or preventing a condition associated with reduced dopaminergic function in a subject, comprising administering to the subject NuIP or an analog or fragment thereof. Methods of inhibiting the activity of Nurr1 in a cell comprising contacting the cell with a NuIP inhibitor are provided. Methods of screening for agents that modulate the interaction of Nurr1 and NuIP are also provided. | 11-03-2011 |
| 20100119450 | SOLUBLE LOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN BINDS DIRECTLY TO ALZHEIMER'S AMYLOID-BETA PEPTIDE - A soluble derivative of low-density lipoprotein receptor related protein-1 (sLRP-1) binds directly to Alzheimer's amyloid-β peptide (Aβ). This binding may be used to detect Aβ or to separate Aβ from the rest of a subject's body. In Alzheimer's disease, it may be used to provide diagnostic results by detecting Aβ, treatment by removing Aβ, or both. | 05-13-2010 |